The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
Official Title: A Phase 1/2 Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma
Study ID: NCT00794417
Brief Summary: The purpose of the study was to determine whether the combination of aflibercept, pemetrexed and cisplatin is safe and effective in treating non-small cell lung cancer (NSCLC).
Detailed Description: The study was conducted in two phases. In phase 1, patients with advanced cancer received different doses of aflibercept in combination with approved doses of pemetrexed and cisplatin. The objective of phase 1 was to determine the safest dose of the combined study medications. This dose was administered to patients with previously untreated NSCLC in phase 2. The phase 2 portion of the study determined if the combination is effective in treating NSCLC.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Arizona Cancer Institute, LLC, Tucson, Arizona, United States
University of Arkansas for Medical Science, Little Rock, Arkansas, United States
Stanford University Medical Center, Stanford, California, United States
Palm Beach Institute of Hematology and Oncology, Boynton Beach, Florida, United States
Edward Hines Jr. VA Medical Center, Hines, Illinois, United States
Kentucky Cancer Clinic, Hazard, Kentucky, United States
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
UNM Cancer Clinic, Albuquerque, New Mexico, United States
Montefiore Medical Center, Bronx, New York, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Presbyterian Hospital Center for Cancer Research, Charlotte, North Carolina, United States
Erie Regional Cancer Center, Erie, Pennsylvania, United States
Schiffler Cancer Center - Medical Oncology Division, Wheeling, West Virginia, United States
Princess Margaret Hospital, Toronto, Ontario, Canada
Name: Clinical Trial Management
Affiliation: Regeneron Pharmaceuticals
Role: STUDY_DIRECTOR